PROCEPT BioRobotics Corporation (PRCT) SEC Filings & Earnings Calls
EquiReason read 13 PROCEPT BioRobotics Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-10-02 — PROCEPT BioRobotics appointed Dr. Michael Mack as independent Class II director, increasing board size to 10. Dr. Mack is a cardiac surgeon with extensive leadership experience..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
5 Aug 202610-QQ2 2026 revenue growth of 19.3% YoY but net loss widened; no explicit guidance.earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · Q2-2026 | $94M | +19% y/y |
| U.S. System Sales and Leases · U.S. · Q2-2026 | $29M | +32% y/y |
| Handpieces and Other Consumables · U.S. · Q2-2026 | $48M | +12% y/y |
| Gross Profit · Q2-2026 | $62M | +21% y/y |
| Net Loss · Q2-2026 | $-27M | |
| Cash and Cash Equivalents · 2026-06-30 | $228M | |
| Operating Cash Flow · H1-2026 | $-57M |
Risks flagged
Operating Loss and Cash Burn
“Net loss $26.9 million for Q2 2026; cash used in operations $57.4 million H1 2026.”
No Explicit Guidance
“No forward-looking guidance statements found in the filing text.”
4 Aug 20268-K · 2.02Total Revenue $94M (+19% y/y); U.S. Revenue $83M (+20% y/y); International Revenue $11M (+15% y/y); Guidance: Revenue guidance $390-410M; U.S. procedure guidance raised to 54,000-56,000earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · Q2-2026 | $95M | +19% y/y |
| U.S. Revenue · U.S. · Q2-2026 | $83M | +20% y/y |
| International Revenue · International · Q2-2026 | $11M | +15% y/y |
| Gross Margin · Q2-2026 | 66.0% | |
| Net Loss · Q2-2026 | $-27M | |
| Adjusted EBITDA Loss · Q2-2026 | $-11M | |
| Cash and Equivalents · Q2-2026 | $231M | |
| U.S. Handpiece ASP · U.S. · Q2-2026 | $3550.00 | +11% y/y |
Guidance
Revenue guidance $390-410M; U.S. procedure guidance raised to 54,000-56,000
Revenue guidance reiterated; procedure guidance raised; gross margin guidance maintained at ~65%.
Risks flagged
Net loss increased to $26.9M from $19.6M due to higher operating expenses.
“Net loss $26.9M vs $19.6M prior year.”
Adjusted EBITDA loss widened to $11.3M from $8.0M.
“Adjusted EBITDA loss $11.3M vs $8.0M.”
30 Apr 202610-QRevenue $83M (+20% y/y); Gross Profit $54M (+22% y/y); Gross Margin 64.9open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $83M | +20% y/y |
| Gross Profit · Q1-2026 | $54M | +22% y/y |
| Gross Margin · Q1-2026 | 64.9% | |
| Net Loss · Q1-2026 | $-32M | |
| Operating Cash Flow · Q1-2026 | $-38M | |
| Cash and Cash Equivalents · 2026-03-31 | $246M | |
| U.S. System Sales and Rentals · U.S. · Q1-2026 | $23M | +25% y/y |
| Handpieces and Other Consumables · U.S. · Q1-2026 | $43M | +13% y/y |
| Service Revenue · U.S. · Q1-2026 | $6M | +56% y/y |
| Outside U.S. Revenue · Outside U.S. · Q1-2026 | $11M | +25% y/y |
Risks flagged
Cash burn acceleration
“Net cash used in operating activities (38,127) (16,980)” · word for word
Widening net loss
“Net loss (31,638) (24,737)”
29 Apr 20268-K · 2.02Total revenue $83M (+20% y/y); U.S. procedures 12,200 (+30% y/y); U.S. systems sold 49; Guidance: FY2026 revenue guidance $390-410M; gross margin ~65%; adjusted EBITDA loss $30-17Mearningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q1-2026 | $83M | +20% y/y |
| U.S. procedures · U.S. · Q1-2026 | 12,200 | +30% y/y |
| U.S. systems sold · U.S. · Q1-2026 | 49 | |
| U.S. install base · U.S. · Q1-2026 | 765 | +40% y/y |
| Gross margin · Q1-2026 | 65.0% | |
| Net loss · Q1-2026 | $-32M | |
| Adjusted EBITDA · Q1-2026 | $-18M | |
| Cash and equivalents · Q1-2026 | $249M |
Guidance
FY2026 revenue guidance $390-410M; gross margin ~65%; adjusted EBITDA loss $30-17M
Q1 beat with strong procedure growth; full-year guidance reaffirmed; margin improving.
Risks flagged
Tariff expense increased and impacted gross margin; ongoing tariff risk could pressure margins.
“Gross margin increase ... offset by inventory cost capitalization and increased tariff expense”
Operating expenses increased to $86.6M from $71.6M, driven by commercial expansion and R&D; profitability still negative.
“Operating expenses in the first quarter of 2026 were $86.6 million, compared with $71.6 million” · word for word
22 Apr 2026DEF 14ACEO transition completed with retirement of Dr. Zadno and appointment of Mr. Wood; proxy discloses compensation details.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $308M | +37% y/y |
| U.S. Procedures · US · FY2025 | 43,300 | +56% y/y |
| U.S. Installed Base · US · FY2025 | 718 | +42% y/y |
| Gross Margin · FY2025 | 64.0% | |
| Net Income · FY2025 | $-96M | |
| Employees · FY2025 | 888 | +17% y/y |
Risks flagged
CEO transition execution risk
“Mr. Wood was appointed as President and Chief Executive Officer effective September 2, 2025.” · word for word
Revenue concentration on single product platform
“We develop, manufacture and sell the AquaBeam ® Robotic System and HYDROS ® Robotic System” · word for word
6 Mar 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
No material risk signals; routine board appointment
26 Feb 202610-KRevenue $308M (+37% y/y); Net Loss $-96M (-5% y/y); Install Base 912 (+27% y/y)open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $308M | +37% y/y |
| Net Loss · FY2025 | $-96M | -5% y/y |
| Install Base · 2025-12-31 | 912 | +27% y/y |
| Accumulated Deficit · 2025-12-31 | $642M |
Risks flagged
History of losses and uncertainty of profitability
“We have a history of significant net losses, we expect to continue to incur operating losses for the foreseeable future and we may not be able to achieve or sustain profitability.” · word for word
Dependence on single product line
“Our revenue is primarily generated from sales of our robotic systems and the accompanying single-use disposable handpieces, and we are therefore highly dependent on the success of those products.” · word for word
Reimbursement risk
“We may not be able to maintain adequate levels of third-party coverage and reimbursement, and third parties may rescind or modify their coverage or delay payments related to our products.” · word for word
5 Nov 202510-QQ3 2025 results: revenue +43% YoY, gross margin improved, operating loss narrowed, cash burn reduced.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $83M | +43% y/y |
| Net loss · Q3-2025 | $-21M | +2% y/y |
| Gross profit · Q3-2025 | $54M | +46% y/y |
| Cash and cash equivalents · Q3-2025 | $294M |
Guidance
No explicit guidance; forward-looking statements caution
No formal guidance; strong revenue growth and margin improvement suggest positive trajectory.
Risks flagged
Competitive market; rapid technological change
“We operate in a very competitive and rapidly changing environment.” · word for word
Dependence on FDA clearance and adoption
“The Company received 510(k) clearance from the FDA for its next generation robot system, HYDROS® Robotic System.” · word for word
CEO transition risk
“On September 1, 2025, the Company’s former CEO retired.” · word for word
4 Nov 20258-K · 2.02Total revenue $83M (+43% y/y); U.S. handpiece and consumables revenue $44M (+50% y/y); U.S. system and rental revenue $25M (+26% y/y); Guidance: FY2026 revenue guidance $410-430M (26-32% growth); FY2025 reiterated at ~$325.5Mearningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q3-2025 | $83M | +43% y/y |
| U.S. handpiece and consumables revenue · U.S. · Q3-2025 | $44M | +50% y/y |
| U.S. system and rental revenue · U.S. · Q3-2025 | $25M | +26% y/y |
| International revenue · International · Q3-2025 | $9M | +53% y/y |
| U.S. install base · U.S. · Q3-2025 | 653 | |
| Gross margin · Q3-2025 | 65.0% | |
| Net loss · Q3-2025 | $-21M | |
| Adjusted EBITDA · Q3-2025 | $-7M | |
| Cash, cash equivalents and restricted cash · Q3-2025 | $297M | |
| FY2025 revenue guidance · FY2025 | $326M | +45% y/y |
Guidance
FY2026 revenue guidance $410-430M (26-32% growth); FY2025 reiterated at ~$325.5M
Strong Q3 beat and first-time FY2026 guidance above consensus; management confident in growth trajectory.
Risks flagged
Tariff cost headwind expected in Q4 2025
“The Company expects a gross margin headwind of approximately $2.0 million in the fourth quarter, attributable to tariff-related costs.” · word for word
Operating expenses increasing faster than revenue
“Operating expenses in the third quarter of 2025 were $77.2 million, compared with $59.3 million in the prior year period.” · word for word
PROCEPT BioRobotics Corporation — questions
- What did PROCEPT BioRobotics Corporation file recently?
- 13 SEC filings in the last 12 months. Latest: 8-K on 2026-10-02 — PROCEPT BioRobotics appointed Dr. Michael Mack as independent Class II director, increasing board size to 10. Dr. Mack is a cardiac surgeon with extensive leadership experience.
Every figure on this page comes from PROCEPT BioRobotics Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.